SAB, BARDA Contract for MERS Treatment
News Aug 25, 2016
SAB Biotherapeutics, Inc. (SAB) announced that it has been awarded a contract for up to $5.3 million by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (HHS). The funding will be used for advanced clinical manufacturing and testing for SAB’s novel antibody therapeutic (SAB-301) to treat MERS-CoV.
“SAB has developed a unique production platform to rapidly respond to emerging infectious disease threats,” said SAB president and CEO Dr. Eddie Sullivan. “This partnership with BARDA is instrumental in advancing the MERS treatment, while creating a clinical development pathway for other therapeutics produced from our novel rapid response platform.”
SAB-301 was produced utilizing the DiversitAb™ platform, which leverages transchromosomic cattle (Tc Bovine™). These cattle have been genetically designed to produce large amounts of human polyclonal antibodies (immunoglobulin G) in response to an antigen such as MERS in a brief period of time.
Currently, there are no approved vaccines or specific treatments for MERS, a severe respiratory disease akin to the Severe Acute Respiratory Syndrome (SARS) with a high fatality rate. Since it was first identified in Saudi Arabia in 2012, MERS has infected more than 1,700 people and killed nearly 40% of those infected. According to the World Health Organization, cases have now been confirmed in 27 countries in the Middle East, Europe, Asia and the United States. A 2015 outbreak in the Republic of Korea is the largest outbreak outside of the Middle East.
BARDA, which manages the procurement and advanced development of medical countermeasures for pandemic influenza and other emerging infectious diseases, will provide an initial $2.4M for clinical grade product for human trials, with an option for an additional $2.9M to produce more doses if needed.
Phase I Clinical Trials are currently underway for SAB-301 with the National Institutes of Health (NIH) evaluating dosage and safety with a final report expected in the first quarter of 2017. Once these trials in healthy candidates have been completed with no significant safety concerns, the potency and dosing of the treatment can be evaluated in Phase 2 trials in patients with MERS in endemic countries utilizing the product specified in the BARDA contract also conducted by the NIH.
“We are also advancing treatments for Ebola, Influenza and Zika with the goal of leveraging our platform as a countermeasure against emerging infectious diseases,” added Sullivan. “SAB is dedicated to partnering with government and other organizations to address this current and future threats [sic] to human health.”
Deficiency of Innate Immune Adaptor TRIF Linked to NeurodegenerationNews
Research has revealed that deficiency of the innate immune adaptor TRIF, which is essential for certain Toll-like receptor signaling cascades, significantly shortened survival time of ALS mice.READ MORE
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
‘Bad’ Antibodies Provide Crucial Protection Against Invading MicrobesNews
In a world first, scientists have revealed how a population of 'bad' antibodies in the immune system - which are usually 'silenced' because they can harm the body - can provide crucial protection against invading microbes.
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018